Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib Maintenance to Prevent Post-Transplant Relapse in MPNs
NCT05127174Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fedratinib in Myeloproliferative Neoplasm (MPN) (4 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Recommended Phase 2 Dose at 1 year and Progression Free Survival at 1 year. Started Mar 2022; status: terminated.
02
Drugs
fedratinib
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT05127174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127174.